The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Expect brakes to be off soon
It seems a lot of people have different expectations how this could pan out, I guess options differ on what news is expected first, plenty to speculate on.
We also had the virtual partnering event which could also generate a new interest, given the degree of experience and status of the attendees it would be a fantastic opportunity for Nigel to show off Nuvec for all applications and you can bet that exactly why they listed.
Agreed, just my opinion but I believe we’ll see updates on the gene therapy side first. I keep repeating this because it seems they’ve adopted the particle uses and tested alongside other use cases and arrived with this idea of using Nuvec to produce the reagent, this is a crazy opportunity if it succeeds!
£80K plus in buys in last 30 mins? News?
I think the evidence is there to show potential. But as it stands, it’s exactly that - potential.
Unless you get in early, it will always be too late to fully capitalise. But bear in mind the price was slowly creeping before the 50m share addition, 15 to 25p is probably the upper limit based on hype and it’s liable to drop if this dies. As soon as Evotec come with some news the price should rise and maintain a new base, which will be much higher than the recent 4-6p
Leistertheinvestor: I think you only have to look at NCYT to work out any price predictions and it will be just as rapid.
You cant wait for good news to come before jumping on board here....It will rocket so quickly you just wont get the chance....When it hits 50% in minutes you will be scared to jump on in case its spiked so you will leave it ...then up to 100% 200% 300% just like NCYT....You have to get in now to eliminate any risk of missing out.
Thanks. It doesn’t sound impossible to do that, we’ve seen lately the rises that’s happened with the big testing company’s and I understand it’s not in the same league it does show there was early rises building up on sentiment alone, way before sales landed. But we have a delivery system that could go into multiple revenue streams and potential far outsell the testing companies long term.
I think 15-25p should be easily reachable just on what I did last time we had the Medlmmune collaboration, and as far as we know that wasn’t axed totally, that could rise it’s head any time if the key tasks they stipulated have been met. My guess is they would have specified the reliable productionOf Nuvec in quantity could be achieved before they committed further funding and resources.
30-40p short term! Oops
I’ve a few quid built up in here over the last while. Most I’ve paid is 7p per share.
Realistically I would expect £0.30-0.40 in the short to medium term and £1-2 in the medium to long term with a positive outlook on the impending RNS
Unfortunately a lot of the prices are dependant on trends and rampers. It can be volatile and can shift upwards very quickly if the wind catches the sail on Twitter, influx of buyers hoping for a quick flip.
I’m in for the long haul, but won’t hesitate to sell if I feel it has reached its ceiling in the future
The bonus with this is, it’s not just a Covid connected delivery system. It’s great the bod took the chance to showcase Nuvec in this situation and hopefully it gets recognition for potentially being a best in class delivery system. The company has positioned Nuvec in more than one sector which improves the success rate and hopefully returns great reward to the company and investors.
As results unfold I expect institutions to take more of the free float and it’s this what will drive the share price up. This was achieving 30+% in a day on no news a few weeks back, hopefully we’re likely to build up to these moves soon especially as news becomes imminent.
Anyone have any price predictions? Just curious what people are expecting.
I only have a small holding here but I for one hope that N4p can be part of the process that deliver a Covid or any other vaccine for diseases. The involvement of Evotec who are party to the Covid solution must be a very positive step for N4p. Good Luck to them and all holders here. Looks quite positive.